Epidemiologic study of analgesic abuse: Mortality study in 7275 working women (1968–1987)  by Dubach, Ulrich C. et al.
Kidney International, Vol. 40 (1991), pp. 728—733
Epidemiologic study of analgesic abuse: Mortality study in
7275 working women (1968—1987)
ULRICH C. DUBACH, BERNARD ROSNER, and TIL STURMER
Medizinische Universitäts-Poliklinik, Departement innere Medizin, Kantonsspital, 4031 Base!, Switzerland, and Channing Laboratory,
Harvard Medical School, Boston, Massachusetts, USA
Epidemiologic study of analgesic abuse: Mortality study in 7275 work-
ing women (1968—1987). In a prospective, longitudinal investigation over
a period of 20 years in 7275 working women 30 to 49 years old, we
examined the effect of the ingestion of analgesics on cause-specific
mortality. Evidence of intake of phenacetin and salicylate containing
analgesics was obtained at a urine screening in 1967 and was shown to
relate to intake between 1968 to 1978. Life table analysis of the effect of
phenacetin intake on overall mortality showed significant differences
between the groups of women with intake (N = 613) versus no intake (N
= 4175): for total [relative risk (RR) = 2.1, P < 0.001], urorenal (RR =
24.4, P < 0.001), cardiovascular (RR = 4.5, P < 0.001), and cancer
mortality (RR = 1.9, P < 0.001). No significant effects on overall or
cause-specific mortality were found for salicylate intake. These results
make a causal relationship between the amount of analgesic containing
phenacetin consumed and the risk of death from urorenal disease likely.
Furthermore, the data show an elevated risk for cardiovascular disease
and cancer for phenacetin intake. No such relationships are demonstra-
ble for the use of salicylate.
Since SpUhler and Zollinger suggested in 1953 that analgesic
drugs could cause chronic renal disease [1], much work has
been done on the relation between prolonged ingestion of
analgesics and development of renal disease [2, 3]. However,
none of the previous investigations were longitudinal, most
were retrospective, and few used objective data to determine
analgesic use. As a result, none could show whether excessive
or prolonged use of analgesics by healthy persons could cause
renal disorders [4].
In 1967 a study was designed to ascertain the incidence of
renal disease in apparently healthy women 30 to 49 years old
who took phenacetin-containing analgesics regularly, relative to
the incidence in similar women who took such analgesics less
regularly or not at all [5].
The study was conducted in four steps. Step 1 (completed in
1968) was a two-stage screening procedure on 7275 women to
assemble a study group of 623 women from 30 to 49 years of age
with evidence of a high intake of phenacetin-containing analge-
sics, as well as a matched control group of 621 women with no
evidence of such intake. Step 2 (also completed in 1968)
consisted of interviewing and examining both groups (baseline).
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Step 3 (completed in 1978) consisted of a follow-up of these
1244 women, including examinations from 1969 to 1972 every
year, as well as examinations in 1975 and 1978. Steps 1 to 3 have
been reported in detail elsewhere [6—8].
In a previous report we considered total and cause-specific
mortality as well as cardiovascular morbidity during a 20 year
follow-up period from 1968 to 1987 in the cohort of 1244
matched women [9]. In the present report (step 4) we extend the
mortality findings to all 7275 persons screened for analgesic
intake at the start of our study in 1967; in addition we consider
the effects of salicylate on mortality.
Methods
To establish a population of apparently healthy women with
analgesic abuse, women who were employed in various enter-
prises in northwestern Switzerland were screened for analgesic
intake in 1967. Employers at 88 enterprises agreed to allow their
employees to participate in the study on a voluntary basis.
These companies, employing about 13,000 women of ages 30 to
49, manufactured watches, pharmaceuticals and chemicals,
metallurgic products, textiles, food, tobacco and paper, and
were also involved in retailing, banking and insurance. In the
first screening, letters offering health evaluation for detection of
kidney disease were written to women employees 30 to 49 years
old and were signed by the employers. On the day of the first
contact, urine was collected from each of the 7275 women who
agreed to be screened by a field team consisting of a physician,
a nurse and a laboratory technician. A short questionnaire that
asked for the participant's name, age, marital status, national-
ity, parity and occupation was completed and handwritten on a
filing card. Two additional urine specimens spontaneously
voided at home on two days within a week after the first contact
were mailed to us.
All three urine samples were analyzed for the presence of
N-acetyl-p-aminophenol (NAPAP), the main metabolite of
phenacetin [101, and specimens showing readings above an
optical density of 0.047 (> 0.18 mmol/liter) were considered
positive [11]. If none of the three samples submitted was
positive, the participant was considered to be NAPAP negative;
if one or more of the three specimens were positive the woman
was screened further. The three urine samples were also
analyzed for the presence of salicylate by a colorimetric
method. A specimen containing 20 mg or more per 100 ml (1.46
mmol per liter) was regarded as positive [11]. An individual was
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classified as positive for salicylate, if one or more of the three
samples submitted was positive, negative if all three specimens
were below that level, and unknown if any of the three
specimens was missing. In a second screening six to eight
weeks after the first, all women who had one or more specimens
that were positive for NAPAP at the first screening were
approached at their place of work and asked to submit one urine
sample immediately and to mail two more from home within the
next week. These three specimens were also analyzed for
presence of NAPAP and salicylate. A woman with one or more
positive urine samples for NAPAP at both the first and second
screening was considered as NAPAP positive (study group, N
= 623). All other women were considered as NAPAP negative
and 621 women were matched as a control group. The likely
heterogeneity of the group taking phenacetin with respect to the
amount of analgesics ingested was recognized. Therefore, a
mean NAPAP score (x) was computed based on the six NAPAP
values obtained in 1967. Women in the study group were
classified as high NAPAP (x  0.77 mmol per liter) and low
NAPAP otherwise.
The screening procedure allowed us to establish a group with
objective evidence for regular intake of phenacetin containing
analgesics and a matched group without such evidence, for a
total of 1244 women for our "Swiss Analgesic Study" [8, 9].
This cohort was followed for morbidity and mortality until the
end of 1987; 1008 women were still living in Switzerland, 135
left Switzerland (lost to follow-up) and 10? have died. Mortality
and morbidity, results for this cohort were analyzed separately
and are published elsewhere [9].
To get further data on mortality related to analgesic use,
mortality follow-up was also obtained through 1987 for the
remaining women (N = 6031) who were screened in 1967.
Questionnaires were sent to the 84 still existing enterprises (out
of 88) asking for each woman on the 1967 list: is the woman still
working in the enterprise or getting retirement pay in 1988 (in
which case the woman was counted as alive); if not, in what
year did she leave the enterprise and did she remain in Swit-
zerland or has the woman died (if "yes", where and when?).
Fifty-six lists were sent back to us and resulted in end-point
follow-up ascertainment for 1905 women (32%) (1541 living, 293
left Switzerland and 71 deaths).
Women with incomplete follow-up based on the enterprise (N
= 4126) were followed up using information available in the
communities they lived in either in 1967 or when they had left
the respective enterprise. Information was available from the
"Bureau of Population Control" in local communities in Swit-
zerland where every current or former resident of a community
is registered and must provide a new address when leaving the
community. Lists of women were sent to 382 different villages
and towns. For every woman, the Bureau provided one of the
following responses: still living in the community in 1988; left
Switzerland and in which year; left the community but re-
mained in Switzerland (year left and new address was provid-
ed); died with date and place of death; not found in the records.
This procedure was followed for up to three communities within
Switzerland per woman. Women who lived in more than three
locations within Switzerland over a 20 year period were treated
as alive at the time of the last move, but were not followed
further.
Using these procedures, we obtained the following follow-up
Table 1. Follow-up status of the total cohort as of 12/31/87
Status N % N %
Alive, complete follow-up
Dead
Alive, partial followupa
Left Switzerland'
Remained in Switzerland
No follow-up
4720
345
1976
234
65
5
27
3
1761
215
24
3
Total 7275
a Follow-up ceased prior to 1987; alive as of last date of follow-upb As of date of last follow-up
results for the total cohort of 7275 women (including the "Swiss
Analgesic Study" cohort of 1244 women) over a 20 year period:
5065 (70%) of women had a complete follow-up, of whom 4720
(65%) were still living as of December 31, 1987 and 345 (5%)
were dead. Among the remaining 2210 women, partial follow-up
was accomplished for 1976 women, of whom 1761 (24%) left
Switzerland and 215 (3%) remained within the country. No
follow-up could be obtained for 234 (3%) of the total cohort.
One hundred and one of the 345 women reported as dead before
December 31, 1987 were participants in the "Swiss Analgesic
Study" and had well-documented causes of death [9]. Of the
remaining 244 deaths, 27 women died outside of Switzerland
and no further information on cause of death could be obtained.
The demographic data collected (date of birth, date of death,
place of death, community and nationality) of all the 217 women
reported as having died in Switzerland were sent to the "Fed-
eral Bureau of Statistics" in Berne, where all death certificates
of people having died in Switzerland are available on computer.
A computer matching algorithm was used to obtain the primary
cause of death for 216 of 217 women (lCD, 8th revision, 1969).
Statistical methods
A life table analysis adjusting for year of birth and length of
follow-up was performed [12]. The total study group (the
high-NAPAP subgroup and the low-NAPAP subgroup) were
each compared with the control group for total mortality as well
as urorenal, cancer and cardiovascular mortality. The test-
based method was used to obtain 95% confidence limits for the
relative risk estimates. The joint effects of salicylates and
phenacetin intake were assessed by: a) looking at the effects of
salicylate after controlling for initial age, length of follow-up
and baseline NAPAP group (high NAPAP/low NAPAP/con-
trol); and b) by looking at the effect of NAPAP versus control
after controlling for initial age, length of follow-up and baseline
salicylate group.
Results
The number of deaths and the women lost to follow-up are
reported in Table 1. A total of 5% of women died and only 3%
were totally lost to follow-up among the total group of 7275
women who were screened in 1967. Partial follow-up was
possible for 1976 women (27%).
The expected total and cause-specific number of deaths were
computed by referring to the age- and year-specific mortality
rates for the general female Swiss population during the period
of 1968 to 1987, obtained from the Schweizerisches Bundesamt
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Table 2. Mortality rate in cohorta over time in compariso
general Swiss population
n with the
Cause of death
Number of deaths
SMRbObserved Expected
Urorenal
Cancer
Cardiovascular
20 6.4
156 155,5
77 72.5
3.1
1.0
1.1
TotaIc 322 334.4 1.0
a Among 6674 women who had NAPAP readings at baseline, and who
provided at least some follow-up for vital status
' Standardized mortality ratio
C Since some participants had multiple causes of death and the above
causes of death are not exhaustive, the total number of deaths (322)
does not correspond to the total from specific causes listed above
für Statistik. These age- and time period-specific general popu-
lation mortality rates were then multiplied by the corresponding
person-time experienced by the cohort to obtain the expected
number of deaths. The standardized mortality ratios (SMR)
were then computed by dividing the observed number of deaths
by the expected number of deaths, as computed in Table 2. The
SMR for total mortality in the cohort of all women with
complete or partial follow-up was 1.0. The SMR for specific
causes of death was markedly increased only for urorenal
causes of death (3.1).
The life table analysis of the effect of NAPAP level on overall
mortality adjusted for year of birth and length of follow-up is
shown in Table 3. The death rate over 20 years was 14.4%,
10.0% and 5.8% in the high NAPAP subgroup, low NAPAP
subgroup and control group, respectively, with a relative risk of
death for the total study group versus the control group of 2.1 (P
<0.001).
In Table 4 we consider cause-specific mortality. As regards to
mortality due to urorenal causes, the incidence rates were 2.6%
in the study group and 0.1% in the control group. The relative
risk (= RR) of the study group versus the control group was
markedly increased to 24.4 (P < 0.001). Furthermore, a strong
gradient in risk was apparent between the high (RR = 36.0 vs.
control) and low NAPAP subgroups (RR = 9.6 vs. control). For
mortality due to cancer and cardiovascular disease, there was a
significant difference between the total study group versus the
control group (cancer, RR 1.9, P < 0.001; cardiovascular
disease, RR = 4.5, P < 0.001). There was no apparent gradient
in risk between the high and low NAPAP subgroups for either
of these causes of death.
In Table 5, the joint effects of NAPAP and salicylate excre-
tion on mortality are considered. After adjustment for baseline
salicylate excretion, the RR for total mortality in the study
versus the control group was 2.0 (P <0.001). Similarly elevated
risks were found for deaths due to urorenal disease (RR = 15.7,
P < 0.001), cancer (RR = 2.0, P <0.001) and cardiovascular
disease (RR = 3.2, P < 0.001). In a similar analysis, after
controlling for initial NAPAP level, no significant effect of
salicylate was apparent for total mortality (RR = 0.9, P = NS)
or cause-specific mortality (urorenal, RR = 0.8, P = NS;
cancer, RR = 0.8, P = NS; cardiovascular, RR = 1.1, P = NS).
Discussion
This study is the only prospective longitudinal investigation
of the mortality effects of analgesic abuse over a period of two
Table 3. Life table analysis of effect of NAPAP level on overall
mortality adjusted for year of birth, and length of follow-up
Comparison with control
Totala
No. of
deathsb
group
P value
Relative
riskc 95% CI
Study group
High NAPAP
subgroup
Low NAPAP
subgroup
Control
613
320
293
4175
78 (12.7%)
46 (14.4%)
32 (10.0%)
244 (5.8%)
<0.001
<0.001
<0.001
—
2.1
2.3
1.9
1.0
1.7—2.7
1.7—3.1
1.3—2.7
—
group
a Based on 4788 women who had NAPAP readings at baseline, and
for whom the mortality surveillance was completed. Life table analyses
were based on the cohort of 6674 women who provided at least some
follow-up and who had NAPAP readings at baseline
b Over 20 years (1968—1987, inclusive)
C Relative risk as defined in Reference 8
decades. Switzerland was chosen for this investigation because
it had a large population with a marked abuse of analgesics. The
study used laboratory methods in screening for intake of
phenacetin and salicylate containing pills. The presence of its
main metabolite NAPAP in repeated urine samples was taken
as an indicator of regular intake of analgesics.
NAPAP is the most important metabolite of phenacetin, since
up to 89% of an oral dose of phenacetin is excreted in the urine
as NAPAP [11]. About half the subjects tested at random within
12 hours after they had taken one pill containing 250 mg of
phenacetin are likely to have a positive test for NAPAP
according to this criterion; levels of NAPAP  0.77 mmol per
liter in random samples are indicative of greater intake and
might be found in persons taking at least five tablets, each
containing 250 mg of phenacetin, up to 12 hours before urine
collection [11]. Thus, although our screening criteria for select-
ing the study and control groups and the NAPAP-intake sub-
groups were subject to problems of sensitivity and specificity,
we believe that they were justified by previous studies and that
the screening procedure produced a control group consisting of
essentially nonusers, a low-intake subgroup of low to moderate
users and a high-intake subgroup of essentially heavy users.
The reliability of group assignment was assessed by labora-
tory methods in the cohort of 1244 women over a ten year
period. In particular, during the ten year period (6 follow-up
examinations), 79% (1380 of 1741) of the follow-up determina-
tions of the women with high-NAPAP excretion at baseline,
48% (702 of 1469) of the low-NAPAP and 15% (497 of 3408) of
the NAPAP-negative were NAPAP positive. Similarly, among
women who were positive for salicylate at baseline, 43% (515 of
1207) of follow-up examinations were positive as compared
with 10% (507 of 5154) in women who were negative at baseline
[9]. Thus, a differential analgesic intake persists over a ten year
period.
In the 20 years of follow-up of the initially screened women,
only 3% (234 women) were completely lost to follow-up and
27% (1976 women) had partial follow-up (Table 1). Complete
follow-up was obtained for 70% of 7275 women and 5% (345
women) died. The total, cancer and cardiovascular mortality
rates in this study were comparable to mortality rates in the
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Table 4. Life table analysis of effect of NAPAP level on cause-specific mortality adjusted for year of birth, and length of follow-up
Totala
No. of
deaths'
Comparison with control group
P value Relative risk 95% CI
1. Urorenal mortality
Study group 613 16 (2.6%) <0.001 24.4 11.7—50.9
High NAPAP subgroup 320 13 (4.1%) NTSC 36.0 NTS
Low NAPAP subgroup 293 3 (1.0%) NTS 9.6 NTS
Control group 4175 4 (0.1%) 1.0
2, Cancer mortality
Study group 613 34 (5.5%) <0.001 1.9 1.3—2.8
High NAPAP subgroup 320 16 (5.0%) 0.044 1.7 1.0—2.8
Low NAPAP subgroup 293 18 (6.1%) 0.002 2.2 1.3—3.5
Control group 4175 122 (2.9%) 1.0
3. Cardiovascular mortality
Study group 613 32 (5.2%) <0.001 4.5 3.0—6.8
High NAPAP subgroup 320 19 (5.9%) <0.001 4.8 3.0—7.8
Low NAPAP subgroup 293 13 (4.4%) <0.001 4.1 2.3—7.2
Control group 4175 45 (1.1%) 1.0
a Based on 4788 women who had NAPAP readings at baseline, and for whom the mortality surveillance was completed. Life table analyses were
based on the cohort of 6674 women who provided at least some follow-up and who had NAPAP readings at baseline
b Over 20 years (1968—1987, inclusive)
C NTS numbers too small
general Swiss female population. However, the rate of urorenal
mortality experienced by this cohort was about three times that
expected from the Swiss female population.
The present paper after 20 years of follow-up reports on 322
deaths among the cohort of 6674 women who had NAPAP
readings at baseline; among these, 20 were due to urorenal
causes, 156 due to cancer and 77 due to cardiovascular disease.
There was a significantly increased risk of both total and
cause-specific mortality in the study group versus the control
group. However, a dose-response relationship between the high
and low NAPAP group versus control was only apparent for
urorenal death.
This is important evidence that heavy analgesic abuse over
time can lead to severe, deadly urorenal damage; results for
ingestion of smaller quantities of analgesics containing phen-
acetin are more uncertain. Our results may explain why in the
USA, which has a smaller incidence of analgesic abuse (except
for some special geographic areas), no significant correlation
between analgesic intake (assessed by history) and the presence
of terminal kidney failure was obtained [4, 13]. One explanation
for our results is that a threshold level of intake must be reached
before urorenal damage occurs. Another explanation could be
that some women in the low-NAPAP subgroup had been
misclassified at the initial examination in that they were using
analgesics containing phenacetin only irregularly and thus
would belong to the control group.
One hundred and fifty-six deaths due to cancer lead the list
for specific mortality (Table 4). Only small and statistically
insignificant differences representing random fluctuations were
found between the relative risk for the high-NAPAP (RR = 1.7)
and low-NAPAP (RR = 2.2) subgroups versus the control
group. Except for urothelial carcinoma no connection between
analgesic abuse and malignancy has been reported [141. The
relatively modest relative risk and the lack of a dose-response
relationship make it difficult to reach a definitive conclusion.
Seventy-seven cardiovascular deaths constitute the second
most important cause of mortality (Table 4). A surprisingly
strong relative risk (4.5, P < 0.001) is seen for cardiovascular
death in comparing the study versus the control group. Is abuse
of phenacetin containing analgesics a cardiovascular risk fac-
tor? In 1968 at the start of this investigation not all risk factors
for cardiovascular events were known [6]; the results reported
here are adjusted for age, but not for smoking, blood pressure
and blood lipids. Therefore, the interpretation of our results
needs to be done with caution. Analgesics may influence the
cardiovascular system in two ways: by changes in the kidneys
and by action on vessel walls and on hemostasis. Nanra et al
[15] describe a similar high prevalence of cardiovascular disease
in patients with analgesic nephropathy. Stähelin [16] hypothe-
sizes that analgesics increase the noxious action through inhi-
bition of synthesis of prostaglandins in the kidney, and in
addition the cardiovascular risk may be further enhanced by the
well-accepted risk factors of hypertension and hyperlipidemia
observed in patients with chronic renal disease. The pathogen-
esis, however, is not elucidated to date.
Salicylate is known to inhibit platelet aggregation and to
influence cardiovascular mortality and morbidity. It was there-
fore of interest to assess our population which was screened in
1967 for salicylate excretion in urine. We found no protective
effect of salicylate on overall mortality based on 34 deaths (RR
= 0.9) (Table 5) with similar non-significant results for cause-
specific mortality.
Switzerland on December 31, 1986 showed the highest per-
centage (18.1%) of patients with analgesic nephropathy among
patients on renal replacement therapy compared with the 2.4%
average for all members of the EDTA-ERA registry in Europe
[17]. This is suggestive of a geographic pocket of analgesic
abuse in Switzerland which should draw attention to the need to
identify pockets of high incidence and populations that are at
high risk. In these areas physicians should be alerted to the
possibility of underdiagnosing this preventable disease.
Changes in prescription and self-medication of phenacetin-
containing analgesics over the last 20 years have almost eradi-
cated analgesic nephropathy from the United Kingdom and
Sweden. In Switzerland, prescription for analgesics became
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Table 5. Life table analysis of effect of NAPAP and salicylates on mortality after adjustment for year of birth, and length of foilow-up
Relative 95%
NAPAP Salicylatesa Totaib No. of deathsc Effect P value risk CI
1. Total mortality
High NAPAP
High NAPAP
Low NAPAP
Low NAPAP
present
absent
present
absent
132
165
49
232
15 (11.4%)
30 (18.2%)
4 (8.2%)
26 (11.2%)
NAPAPd
High NAPAP'1
Low NAPAPd
Salicylatese
<0.001
<0.001
0,002
0.471
2.0
2.2
1.8
0.9
1.6—2.5
1.6—2.8
1.2—2.6
0.6—1.2
Control group
Control group
present
absent
204
3898
15 (7.4%)
223 (5.7%)
2. Urorenal mortality
High NAPAP
High NAPAP
Low NAPAP
present
absent
present
132
165
49
5 (3.8%)
8 (4.9%)
0 (0.0%)
NAPAP
High NAPAP
Low NAPAP
<0.001
<0.001
NTS
15.7
16.7
10.5
NTS
NTS
NTS
Low NAPAP absent 232 3 (1.3%) Salicylates 0.597 0.8 0.3—2.0
Control group present 204 0 (0.0%)
Control group absent 3898 4 (0.1%)
3. Cancer mortality
High NAPAP
High NAPAP
present
absent
132
165
4 (3.0%)
10 (6.1%)
NAPAP
High NAPAP
<0.001
0.019
2.0
1.8
1.4—2.8
1,1—2.9
Low NAPAP present 49 2 (4.1%) Low NAPAP 0.002 2.2 1.3—3.5
Low NAPAP absent 232 15 (6.5%) Salicylates 0.368 0.8 0.5—1.3
Control group present 204 7 (3.4%)
Control group absent 3898 111(2.8%)
4. Cardiovascular mortality
High NAPAP present 132 7 (5.3%) NAPAP <0.001 3.2 2.2—4.6
High NAPAP absent 165 12 (7.3%) High NAPAP <0.001 2.8 1.8—4.3
Low NAPAP present 49 2 (4.1%) Low NAPAP <0.001 3.3 1.9—5.8
Low NAPAP absent 232 11(4.7%) Salicylates 0.639 1.1 0.7—1.8
Control group present 204 6 (2.9%)
Control group absent 3898 39 (1.0%)
a Salicylates were defined as present at baseline if any of three specimens had a concentration 20 mg% ( 1.46 mmol per liter)b Based on 4680 women who had NAPAP and salicylate readings at baseline and who provided complete follow-up. Life table analyses are based
on 6539 women who had NAPAP and salicylate readings at baseline, and who provided at least some follow-up for vital status
C Over 20 years (1968—1987, inclusive)d Effectof NAPAP vs. control (also high NAPAP vs. control/low NAPAP vs. control) after adjustment for age, length of follow-up and baseline
salicylate level
Effect of salicylates after adjustment for age, length of follow-up and baseline NAPAP group (high NAPAP/low NAPAP/control)
NTS = numbers too small
mandatory in 1982, and combinations of analgesics with psy-
choactive compounds were restricted for over-the-counter sales
to ten pills. In our country fewer younger persons with analge-
sic nephropathy are entering kidney replacement therapy, but
women 60 to 80 years old are still increasing in number for such
treatment. In Australia the withdrawal of compound analgesics
has resulted in a marked decrease of analgesic nephropathy [3,
15]. An explanation for this phenomenon may be due to the fact
that in compound analgesics the psychoactive ingredients such
as caffeine, codeine, etc., lead to a dependence. A NIH consensus
conference on analgesic-associated kidney disease suggested
that sales of analgesics over-the-counter be limited to prepara-
tions containing a single agent, because of the evidence that
combinations of drugs taken over a long period of time cause
chronic renal disease [18].
The results of our prospective, longitudinal epidemiological
study suggest a causal relationship between the amount of
analgesics containing phenacetin consumed and the risk of
death from urorenal disease. We also demonstrated weaker
associations between intake of phenacetin and an increased risk
of cancer and cardiovascular disease. Although our study
demonstrated excess renal morbidity and mortality associated
with phenacetin-containing compounds, this does not necessar-
ily translate into a similar level of risk from acetaminophen-
containing compounds. The potential harm of acetaminophen
would be best assessed by assembling a cohort at the present
time without prior use of phenacetin-containing analgesics. As
to the use of salicylate-containing compounds, no potential
renal harm could be demonstrated in this study.
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